Inventiva at guggenheim healthcare conference: lanifibranor nears key readout

Inventiva (IVA) participated in the 3rd Annual Guggenheim Healthcare Innovation Conference on November 9, 2026, to discuss the upcoming Phase III readout for its lead drug, lanifibranor, which targets metabolic dysfunction-associated fatty liver disease (MASH). The company highlighted the potential turning point for both the firm and the field, emphasizing that the data is anticipated to arrive within nine weeks of the quarter.

Management expressed optimism about the drug's prospects, citing favorable Phase IIb results, including an 18% effect size on fibrosis regression and a 24% effect size on the composite primary endpoint. However, they also stressed the importance of confirming these earlier results in a larger study. The stock price for Inventiva was last quoted at $3.855, up 1.45% from the previous close of $3.80, with a market capitalization of approximately $884 million.

Analysts have set price targets ranging from $10 to $26, indicating significant upside potential if the Phase III trial is successful.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.